CCEL — CryoCell International Inc
NYSE MKT · Healthcare · Medical Care Facilities
$4.16
-$0.04 (-0.84%)
CryoCell International Inc (CCEL) is a medical care facilities company listed on NYSE MKT. It is led by David I. Portnoy, based in 700 Brooker Creek Boulevard, Oldsmar, FL, United States, 34677, with about 82 employees. Cryo-Cell International, Inc. engages in cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells, which are used in regenerative medicine to treat a range of conditions. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Net income was $1.4M. CCEL currently screens at market cap $39.6M and trailing P/E 490.0.
Use this CCEL page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CCEL quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CCEL SEC filings page. Lician reads the product cache first so this HTML stays unique to CryoCell International Inc even when a live quote feed is slow.
About CryoCell International Inc
Cryo-Cell International, Inc. engages in cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells, which are used in regenerative medicine to treat a range of conditions. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
CCEL Key Statistics
Market Cap
$39.60M
Volume
2,556
Previous Close
$4.39
Day Range
$4.05 – $4.60
P/E Ratio
490.00
EPS
$0.05
Revenue
$0.00
Net Income
$402.10K
Gross Profit
$0.00
Free Cash Flow
$0.00
Dividend Yield
11.56%
Employees
82
CCEL Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $402.10K | -$9.52M | $2.77M | $2.08M |
| EPS (Diluted) | $0.05 | -$1.14 | $0.33 | $0.25 |
Total Assets
$64.68M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$560.96K
Operating Cash Flow
$6.01M
Free Cash Flow
$0.00
CryoCell International Inc Company Information
- Chairman & Co-CEO
- David I. Portnoy
- Headquarters
- 700 Brooker Creek Boulevard, Oldsmar, FL, United States, 34677
- Website
- www.cryo-cell.com
- Phone
- 813 749 2100
- IPO / Founded
- 1997-01-21
- Sector
- Healthcare
- Industry
- Medical Care Facilities